Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.
暂无分享,去创建一个
Michael L. Wang | X. Zhang | L. Kwak | Bo Wan | P. Lin | Jing Yang | J. Qian | Q. Yi | Michele J. Wezeman | Long Yu | Xiang Zhang | B. Wan
[1] D. Bharadwaj,et al. The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .
[2] R. Ashman,et al. Fc receptor off-signal in the B cell involves apoptosis. , 1996, Journal of immunology.
[3] M. Pepys,et al. C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.
[4] J. Rossi,et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. , 1998, Leukemia & lymphoma.
[5] Zander,et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. , 1986, Blood.
[6] B. Barlogie,et al. Primary dexamethasone treatment of multiple myeloma. , 1992 .
[7] A. Tienhaara,et al. Serum immunoreactive interleukin‐6 and C‐reactive protein levels in patients with multiple myeloma at diagnosis , 1994, British journal of haematology.
[8] T. Vogt,et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far‐advanced melanoma and soft tissue sarcoma , 2004, Cancer.
[9] L. Pedersen,et al. Urinary Albumin Excretion and its Relationship to C-reactive Protein and Proinflammatory Cytokines in Patients with Cancer and Febrile Neutropenia , 2003, Scandinavian journal of infectious diseases.
[10] T. Kurosaki,et al. Deletion of SHIP or SHP-1 Reveals Two Distinct Pathways for Inhibitory Signaling , 1997, Cell.
[11] Michael L. Wang,et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. , 2006, Cancer cell.
[12] L. Rabbani,et al. Evidence for C-Reactive Protein's Role in (CRP) Vascular Disease: Atherothrombosis, Immuno-Regulation and CRP , 2004, Journal of Thrombosis and Thrombolysis.
[13] Lewis C Cantley,et al. PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.
[14] D. Schenkein,et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Filep,et al. Loss of Pentameric Symmetry of C-reactive Protein Is Associated with Delayed Apoptosis of Human Neutrophils* , 2002, The Journal of Biological Chemistry.
[16] B. Barlogie,et al. Cancer and the Microenvironment , 2004, Cancer Research.
[17] R. Crowell,et al. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. , 1991, Journal of immunology.
[18] B. Barlogie,et al. Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation , 2005, Leukemia & lymphoma.
[19] K. Anderson,et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.
[20] D. Bharadwaj,et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. , 2000, The Journal of clinical investigation.
[21] S. Devaraj,et al. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role , 2005, Current opinion in nephrology and hypertension.
[22] H. Asaoku,et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.
[23] Mark B Pepys,et al. C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.
[24] M. Pepys. C-reactive protein: the role of an ancient protein in modern rheumatology. , 1983, Clinical and experimental rheumatology.
[25] N. Caplen,et al. Short Interfering RNA (siRNA)—Mediated RNA Interference (RNAi) in Human Cells , 2003, Annals of the New York Academy of Sciences.
[26] A. Agrawal,et al. Transactivation of C-Reactive Protein by IL-6 Requires Synergistic Interaction of CCAAT/Enhancer Binding Protein β (C/EBPβ) and Rel p501 , 2001, The Journal of Immunology.
[27] J. Kemp,et al. Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] Elizabeth Yang,et al. Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.
[29] B. Klein,et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.
[30] M. Takemura,et al. Serum‐soluble Fas level determines clinical symptoms and outcome of patients with aggressive non‐Hodgkin's lymphoma , 2000, American journal of hematology.
[31] B. Barlogie,et al. Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations , 1998 .
[32] V. Diehl,et al. Elevation of circulating IL‐6 in patients with acute non‐lymphocytic leukemia , 1994, European journal of haematology.
[33] T. Kinoshita,et al. Elevated serum interleukin‐6 (IL‐6) is derived from neoplastic lymphoid cells in patients with B‐cell non‐Hodgkin's lymphoma: correlation with extent of IL‐6 expression and serum concentration , 1996, British journal of haematology.
[34] A. Berrebi,et al. Secretion of pro‐apoptotic intron 4‐retaining soluble HLA‐G1 by human villous trophoblast , 2002, European journal of immunology.
[35] L. Marnell,et al. C-reactive protein binds to Fc gamma RI in transfected COS cells. , 1995, Journal of immunology.
[36] Kazuhiro Nakamura,et al. Transcriptional Regulation of Fcgr2b Gene by Polymorphic Promoter Region and Its Contribution to Humoral Immune Responses1 , 2002, The Journal of Immunology.
[37] D. Neuberg,et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.
[38] S. Korsmeyer,et al. Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase , 1998, Molecular and Cellular Biology.
[39] F. Lemonnier,et al. Identification of HLA-A*0201-restricted cytotoxic T-cell epitopes of Trypanosoma cruzi TcP2beta protein in HLA-transgenic mice and patients. , 2003, Microbes and infection.
[40] B. Barlogie,et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. , 1994, Blood.